«Corvette Group – says Managing Director Roberto Teruzzi, – is controlled by LBO Investments SpA, a holding company operating in Private Equity manner with long-term industrial perspective, aiming at developing its holdings by respecting the highest ethical and professional standard levels. Besides being managers with a significant capital share, LBO investors are important international investors such as financial institutions, family offices and qualified entrepreneurs. Subsidiary companies are supported in their development plans both for funding and for industrial and managerial aspects, with a professional management structure of the highest level».
Dr. Teruzzi, what is Corvette Group’s operating strategy?
Corvette Group aims at continuous expansion of products’ range and customized services for its customers, with an ever greater commitment in offering to the international pharmaceutical market high quality services, with strict quality control procedures (whose constant and high level is ensured both by internal controls and many customer audits) using the best technologies on the market, while respecting environment and its employees’ safety. Maintaining the technical and manufacturing characteristics and peculiarities of individual subsidiaries, our holding company creates synergies and added value providing them with high quality centralized services in critical and specific areas such as strategy and business development, quality control, investments, compliance with industry regulations, administration, finance and control, purchasing and business general management.
Which markets do you operate on? Who are your final customers?
We supply the leading manufacturers of branded and generic drugs, both in Italy and abroad, and about 50% of our turnover – estimated 58 million euro in 2013 – comes from export. Excellence level of our technical and managerial skills, customer care and constant upgrading of our technological structures, make our Group companies an all-round reference point in their respective fields, offering high quality and reliability services for customers requiring more real and effective integration between their structures and the ones of third parties. One of our main focuses is erdosteine molecule developed by Edmond Pharma and marketed in 36 countries through partnerships with leading companies. Our approach, both geographically and for products and technology, is to create strong partnerships and lasting relationships with customers, to whom are devoted all human, technological and production resources of Corvette Group and its subsidiaries that work only for third parties according to full service concept. In order to increase effectiveness and efficiency levels also a lean manufacturing project has been started with progressive interventions both in structure and organization, whose implementation came from Biologici Italia Laboratories, as well as the introduction of SAP Pharma 4 management platform on January 1st 2013. Lean application and SAP implementation will be also extended to the other companies of the Group.